Browse > Article

Pneumococcal Surface Protein A of Streptococcus pneumoniae Isolates from Koreans  

Kim, Kyung Hyo (Department of Pediatrics, College of Medicine, Ewha Womans University)
Publication Information
Clinical and Experimental Pediatrics / v.48, no.11, 2005 , pp. 1206-1211 More about this Journal
Abstract
Purpose : Pneumococcal protein vaccine based on pneumococcal surface protein A (PspA) is in development with the potential to offer a broad range of protection against different strains. PspA elicits protection in mice against fatal sepsis as well as carriage and lung infection. This study was performed to investigate the frequency of PspA families among Streptococcus pneumoniae recovered from Korean children and adults. Methods : A total of 89 pneumococcal isolates was included in the study. They were capsule serotyped by the slide agglutination assay with commercial antisera. PspA families were determined with polymerase chain reaction using the pair of primers for family 1 and family 2. Results : Seventeen pneumococcal serotypes were found in a total of 89 isolates. PspA typing was able to ascertain 79 of the 89 isolates (88.8 percent). Among these, 20 (22.5 percent) isolates were family 1 PspA, 59 (66.3 percent) were family 2. Moreover, because 9 (10.1 percent) isolates were of positive reactions for both, families 1 and 2 primers, the potential coverage of PspA vaccine was 98.9 percent. PspA families were not associated with age group, source of isolates, or penicillin susceptibility. However, the relative distribution of family 1 isolates to family 2 isolates was significantly different over capsular serotypes. Conclusion : The finding that 98.9 percent of Korean isolates belonging to PspA families 1 and 2 support the hypothesis that a human PspA vaccine covering a few PspA families could be broadly effective. The monitoring of the PspA families derived from large population-based isolates will be necessary in the context of vaccine development.
Keywords
Streptococcus pneumoniae; Pneumococcal surface protein A;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cowan MJ, Ammann AJ, Wara DW, Howie VM, Schultz L, Doyle N, et al. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 1978;62:721-7
2 Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser permanent vaccine study center group. Pediatr Infect Dis J 2000;22:187-95
3 Ren B, McCrory MA, Pass C, Bullard DC, Ballantyne CM, Xu Y, et al. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor- mediated protection. J Immunol 2004;173:7506-12   DOI
4 Vela Coral MC, Fonseca N, Castaneda E, Di Fabio JL, Hollingshead SK, Briles DE. Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis 2001;7:832-6.   DOI   ScienceOn
5 McDaniel LS, Yother J, Vijayakumar M, McGarry L, Guild WR, Briles DE. Use of insertional inactivation to facilate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987;165:381-94   DOI   ScienceOn
6 Briles DE, Hollingshead SK, King JE, Swift A, Braun P, Ferguson LM, et al. Immunization of human volunteers with recombinant PspA elicits antibodies that passively protect mice. J Infect Dis 2000;182:1694-701
7 Swiatlo E, Brooks-Walter A, Briles DE, McDaniel LS. Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniae. Gene 1997;188:279-84   DOI   ScienceOn
8 Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks- Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000;19(Suppl 1):S87-95   DOI   ScienceOn
9 McDaniel LS, Scott G, Kearney JF, Briles DE. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med 1984;160:386-97   DOI   ScienceOn
10 McDaniel LS, Sheffield JS, Delucchi P, Briles DE. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype. Infect Immun 1991;59:222-8
11 Wu H-Y, Nahm M, Guo Y, Russell M, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage and infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997;175:839-46   DOI   ScienceOn
12 Miyaji EN, Dias WO, Gamberini M, Gebara VC, Schenkman RP, Wild J, et al. PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae. Vaccine 2001;20:805-12   DOI   ScienceOn
13 Di Fabio JL, de Quadros C. Considerations for combination vaccine development and use in the developing world. Clin Infect Dis 2001;33(Suppl 4):S340-5   DOI   ScienceOn
14 Miyaji EN, Dias WO, Tanizaki MM, Leite LC. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines : contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 2003;37: 53-7   DOI   ScienceOn
15 Jacobs MR. Streptococcus pneumoniae : epidemiology and patterns of resistance. Am J Med 2004;117(Suppl 3A):3S- 15S   DOI   ScienceOn
16 McDaniel LS, McDaniel DO, Hollingshead SK, Briles DE. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 1998;66:4748-54
17 Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000;18:1743-54   DOI   ScienceOn
18 Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In : Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia : WB Saunders Co, 2004:529-88
19 Cockeran R, Anderson R, Feldman C. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch Immunol Ther Exp 2005;53:189-98
20 Hollingshead SK, Becker R, Briles DE. Diversity of PspA : mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000;68:5889-900   DOI   ScienceOn